New drug R&D is a high risk, high reward, long cycle industry, with very few companies able to finance through loans. Recently, Zhongji IP Fund provided 5 million in venture lending to replenish liquid capital and develop business. 　　Beijing Syngentech Co., Ltd. is the first domestic biotech company focused on synthetic biology in the research, medical and healthcare sector. The company was founded in July 2014, with cutting edge technologies such as tumor identification and gene programming, the company seeks to achieve breakthroughs in liver cancer and leukemia treatment. At the same time, the company engages in high end biological reagent R&D, sales and services, and built the first domestic gene element sharing platform – Gene Mountain, which effectively increased the productivity of healthcare institutions and university research staff. 　　The Syngentech founding team came from national laboratories; with consulting shareholders that include the members of the Thousand Talents Program, China’s 973 Project Chief Scientists and winners of National Science Fund for Distinguished Young Scholars. The company’s tumor identification and gene programming technologies are proprietary and represent the most forerunning technologies. In biological therapy for cancer treatment, Syngentech has a strong R&D team and advanced bio-pharmaceutical technologies, and posts tremendous development potential. 　　As a Zhongguancun New and High Tech Enterprise, and Zhongguancun Bio-Pharmaceutical Industry Alliance member, Syngentech received government funding through “Beijing Returned Overseas Scholars Entrepreneurship Fund” and “Beijing Small and Medium Sized Technology Companies Innovation Fund.”